Drug updated on 11/1/2023
|Tablet (oral: 200 mg, 550 mg)
| Ongoing and
- Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older.
- For reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
- Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Product Monograph / Prescribing Information
|Xifaxan (rifaximin) Prescribing Information.
|Salix Pharmaceuticals, Bridgewater, NJ
Systematic Reviews / Meta-Analyses
|Systematic review and meta-analysis on the effects of lactulose and rifaximin on patient-reported outcomes in hepatic encephalopathy.
|The American Journal of Gastroenterology
|Efficacy of rifaximin in patients with abdominal bloating or distension; a systematic review and meta-analysis.
|Journal of Clinical Gastroenterology
|Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis.
|Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy? A meta-analysis.
|A systematic review of the use of rifaximin for Clostridium difficile infections
|Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
|Drug Design, Development and Therapy